Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 4/2006

Content (16 Articles)

Original Article

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

Jane E Latz, Ajai Chaudhary, Atalanta Ghosh, Robert D Johnson

Original Article

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

Jane E Latz, Mats O Karlsson, James J Rusthoven, Atalanta Ghosh, Robert D Johnson

Original Article

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy

Jane E. Latz, James J. Rusthoven, Mats O. Karlsson, Atalanta Ghosh, Robert D. Johnson

Original Article

Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma

Seok Jin Kim, Hee Yun Seo, Jong Gwon Choi, Hye Ryoung Sul, Hwa Jung Sung, Kyong Hwa Park, In Keun Choi, Sang Cheul Oh, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim

Original Article

Interpreting cell cycle effects of drugs: the case of melphalan

Monica Lupi, Paolo Cappella, Giada Matera, Claudia Natoli, Paolo Ubezio

Original Article

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers

Ramesh K. Ramanathan, Marwan Fakih, Sridhar Mani, Melvin Deutsch, Raymond P. Perez, Mark A. Ritter, Julie L. Eiseman, S. Percy Ivy, Donald L. Trump, Chandra P. Belani, Robert A. Parise, Douglas M. Potter, Merrill J. Egorin

Original Article

Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children

P. Kellie Turner, Lisa C. Iacono, John C. Panetta, Victor M. Santana, Najat C. Daw, Amar Gajjar, Clinton F. Stewart

Original Article

Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro

Jocelyn L Carr, Malcolm D Tingle, Mark J McKeage

Original Article

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells

Maria Serova, Fabien Calvo, François Lokiec, Florence Koeppel, Virginie Poindessous, Annette K. Larsen, Emily S. Van. Laar, Stephen J. Waters, Esteban Cvitkovic, Eric Raymond

Original Article

Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells

Michelutti Angela, Stocchi Raffaella, Candoni Anna, Tiribelli Mario, Calistri Elisabetta, Russo Domenico, Fanin Renato, Damiani Daniela

Original Article

Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells

Yi-Hsien Lin, Jen-Hwey Chiu, Wen-Ser Tseng, Tai-Tong Wong, Shih-Hwa Chiou, Sang-Hue Yen

Original Article

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

Monika Jermann, Rolf A Stahel, Marc Salzberg, Thomas Cerny, Markus Joerger, Silke Gillessen, Rudolf Morant, Fritz Egli, Kaspar Rhyner, Jean A Bauer, Miklos Pless

Original Article

Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

Silwan Chedid, Edgardo Rivera, Debbie K. Frye, Nuhad Ibrahim, Francisco Esteva, Vicente Valero, Gabriel Hortobagyi, Karl L. Mettinger, Massimo Cristofanilli

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine